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Abstract: Extensive research is dedicated to understanding if sporadic and familial papillary thyroid
carcinoma are distinct biological entities. We have previously demonstrated that familial papillary
thyroid cancer (fPTC) cells exhibit short relative telomere length (RTL) in both blood and tissues
and that these features may be associated with chromosome instability. Here, we investigated the
frequency of HER2 (Human Epidermal Growth Factor Receptor 2) amplification, and other recently
reported genetic alterations in sporadic PTC (sPTC) and fPTC, and assessed correlations with RTL
and BRAF mutational status. We analyzed HER2 gene amplification and the integrity of ALK, ETV6,
RET, and BRAF genes by fluorescence in situ hybridization in isolated nuclei and paraffin-embedded
formalin-fixed sections of 13 fPTC and 18 sPTC patients. We analyzed BRAFV600E mutation and RTL
by qRT-PCR. Significant HER2 amplification (p = 0.0076), which was restricted to scattered groups
of cells, was found in fPTC samples. HER2 amplification in fPTCs was invariably associated with
BRAFV600E mutation. RTL was shorter in fPTCs than sPTCs (p < 0.001). No rearrangements of other
tested genes were observed. These findings suggest that the association of HER2 amplification with
BRAFV600E mutation and telomere shortening may represent a marker of tumor aggressiveness, and,
in refractory thyroid cancer, may warrant exploration as a site for targeted therapy.
Keywords: papillary thyroid carcinoma; HER2 (Human Epidermal Growth Factor Receptor 2); Telomere;
FISH (fluorescence in situ hybridization)
1. Introduction
The most common histological subtype of non-medullary thyroid carcinoma (NMTC) is papillary
thyroid carcinoma (PTC), which represents 75%–85% of all thyroid cancer. Although mostly sporadic
(sPTC), there is some evidence for a familial form of PTC (fPTC) not associated with known Mendelian
syndromes. Familial PTC is observed in approximately 5%–10% of NMTC cases [1] and, despite
the extensive research dedicated to understand if it is a distinct biological entity than sPTC [2], this
distinction remains controversial. Indeed, the most common somatic alterations, such as mutations
in RAS and BRAF and rearrangements of RET/PTC and NTRK1, exhibit similar prevalence and
distribution in both sPTC and fPTC [3]. No oncogenic germline mutations of these genes have been
detected in fPTC cases [4]. However, there is an ongoing debate on the possible association of HAPB2
germline mutation to the predisposition to familial forms of NMTC [5–8]. Generally speaking, most
PTC can be treated effectively with surgery and radioactive iodine therapy. However, for cases in
which these treatments are not effective, targeted drugs might be considered. Kinase inhibitors, such
Int. J. Mol. Sci. 2016, 17, 1759; doi:10.3390/ijms17101759 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2016, 17, 1759 2 of 11
as sorafenib and lenvatinib, are now used as targeted drugs [9,10]. Less frequent genetic alterations,
such as rearrangements of ALK [11] and ETV6 [12], identified in sPTC, but not yet investigated in
fPTC, also represent new therapeutic targets. In addition, the amplification of the HER2 gene, reported
in highly-malignant PTC nodules [13], might be added to the list of drug-targetable genes. The
HER2 amplification in PTC was observed by fluorescence in situ hybridization (FISH), and average
telomere length in HER2-positive (HER2+) PTC was significantly shorter than HER2-negative (HER2−)
PTC [13]. Of possible significance, shorter average telomere length has also been reported in fPTC
compared to sPTC [14]. These observations prompted us to verify HER2 amplification and telomere
length status in 13 fPTC and 18 sPTC. Tumors were also investigated for integrity of the RET gene,
which is rearranged in 10%–40% of PTC, and ALK, ETV6, and BRAF genes, which are rearranged in a
minority of PTC. BRAFV600E mutation, which is associated with an aggressive biological behavior [15],
was also evaluated. Our results indicate an increased prevalence of occasional HER2 gene intermediate
amplification in fPTC compared to sPTC, and shorter telomeres in all fPTC, including those with HER2
amplification, compared to sPTC. In addition, all HER2+ samples invariably possessed the BRAFV600E
mutation, but not vice versa. The association might represent a marker of tumor aggressiveness and,
in refractory thyroid cancer, may indicate possible exploration for targeted therapy. Additionally,
the simultaneous occurrence of these three specific molecular alterations may be suggestive of the
existence of a specific fPTC subgroup.
2. Results
2.1. Human Epidermal Growth Factor Receptor 2 (HER2) Amplification in Familial Papillary Thyroid
Carcinoma (fPTC) and Sporadic Papillary Thyroid Carcinoma (sPTC)
HER2 amplification was evaluated in 13 fPTC (seven females, mean age at diagnosis of 53.7 ± 14.2;
six males, mean age at diagnosis 49.0 ± 21.5) and 18 sPTC (15 females, mean age at diagnosis 46.6 ± 7.8;
three males, mean age at diagnosis 43.6 ± 13.6). We found that isolated fPTC and sPTC nuclei
were HER2− according to the Wolff criteria (originally developed for breast cancer formalin-fixed
paraffin-embedded (FFPE) examination) [16], although a number of cases showed scattered HER2+
cells, ranging from 1.4% to 9% in fPTC and from 1% to 2.4% in sPTC (Figure 1A,B). Based on these
observations, and on the lack of specific criteria for the evaluation of HER2 amplification in thyroid
tumors, we analyzed the distribution of HER2+ cells in these cases to determine if they met the criteria
for the presence of genetic heterogeneity (>5% and <50%) according to Vance [17]. We found significant
genetic heterogeneity in the distribution of HER2 amplification in fPTC compared to sPTC (p = 0.0076)
(Figure 1C–E). We found that 5/13 (38.5%) fPTC cases showed 5.1% to 10% HER2+ cells. FISH on FFPE
from sPTC confirmed the findings obtained from isolated nuclei that no sPTC case exceeded the cut-off
value. When fPTCs were analyzed by immunohistochemistry using an anti-c-erbB2 antibody [18] to
detect HER2 protein expression, inconsistent results compared to the FISH analysis were obtained.
However, this result was possibly biased by the age of the available histological sections (7–20 years).
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Figure 1. Distribution of HER2 (human epidermal growth factor receptor 2) amplification in familial 
papillary thyroid carcinoma (fPTC) and sporadic papillary thyroid carcinoma (sPTC) nuclei. Arrows 
point to isolated nuclei with extra copies of the HER2 gene (red spots) in the presence of disomy 17 
(chromosome 17 centromere-specific alphoid repetitive DNA, green spots) in fPTC (A); and sPTC 
(B); and in nuclei in formalin-fixed paraffin-embedded (FFPE) sections of fPTC (C); and sPTC (D). 
The distribution of the amplification in FFPE sections of fPTC versus sPTC was significant (p = 
0.0076) (Fisher exact test) and indicative of genetic heterogeneity heterogeneity according to Vance 
criteria [17] (E). Scare bar = 10 µm. 
2.2. Rearrangements of ALK, BRAF, ETV6, and RET Genes 
We found no rearrangements of ALK, BRAF, and ETV6 genes by fluorescence in situ 
hybridization. We found one case of sPTC with a RET rearrangement, the remaining cases exhibited 
neither disruptions nor numerical changes in RET gene (see examples in Figure 2A,B). 
 
Figure 2. Examples of fluorescence in situ hybridization (FISH) in isolated nuclei for the 
identification of genes specifically rearranged in papillary thyroid carcinoma (PTC). Arrows point to 
the split of the red/green signal of a RET break-apart [19] probe in the case of sPTC, indicating broken 
RET (A); and to un-split red/green signals of an ALK break-apart probe in the case of fPTC, indicating 
unbroken ALK (B). Red spot: 300 kb probe DNA fragment; Green spot: 442 kb probe DNA fragment; 
Scare bar = 10 µm. 
Figure 1. Distribution of HER2 (human epidermal growth factor receptor 2) amplification in familial
papillary thyroid carcinoma (fPTC) and sporadic papillary thyroid carcinoma (sPTC) nuclei. Arrows
point to isolated nuclei with extra copies of the HER2 gene (red spots) in the presence of disomy
17 (chromosome 17 centromere-specific alphoid repetitive DNA, green spots) in fPTC (A); and
sPTC (B); and in nuclei in formalin-fixed paraffin-embedded (FFPE) sections of fPTC (C); and sPTC
(D). The distribution of the amplification in FFPE sections of fPTC versus sPTC was significant
(p = 0.0076) (Fisher exact test) and indicative of genetic heterogeneity heterogeneity according to
Vance criteria [17] (E). Scare bar = 10 µm.
2.2. Rearrangements of ALK, BRAF, ETV6, and RET Genes
We found no rearrangements of ALK, BRAF, and ETV6 genes by fluorescence in situ hybridization.
We found one case of sPTC with a RET rearrangement, the remaining cases exhibited neither
disruptions nor numerical changes in RET gene (see examples in Figure 2A,B).
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Figure 2. Examples of fluorescence in situ hybridization (FISH) in isolated nuclei for the identification
of genes specifically rearranged in papillary thyroid carcinoma (PTC). Arrows point to the split of
the red/green signal of a RET break-apart [19] probe in the case of sPTC, indicating broken RET (A);
and to un-split red/green signals of an ALK break-apart probe in the case of fPTC, indicating unbroken
ALK (B). Red spot: 300 kb probe DNA fragment; Green spot: 442 kb probe DNA fragment; Scare
bar = 10 µm.
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2.3. Telomere Length and BRAFV600E Mutation in fPTC and sPTC Patients
Relative telomere length was significantly shorter in fPTC samples than in sPTC samples:
median = 0.93 (25th–75th percentile: 0.6–1.2) vs. 1.9 (25th–75th percentile: 1.8–2.3) for fPTC vs.
sPTC, respectively (p < 0.001) (Figure 3). This result was not due to a difference in the patient’s age
and sex, as sporadic cases were selected to be age/sex-matched with familial patients (Table 1).
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BRAFV600E mutation was detected in 9/13 (69.0%) fPTC and 14/18 (78%) sPTC (p = 0.68), which 
was not statistically significant. All HER2+ fPTC were BRAFV600E-positive (BRAF+), although not all 
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Figure 4. Distribution of HER2 amplification and BRAFV600E mutation in fPTC and sPTC tumors. 
 
Figure 3. fPTC and sPTC relative telomere le TL). RTL was measured by q-PCR, and was
expressed as the ratio (T/S) of the telomere (T) repeat copy number to a single-copy gene (S).
The difference in RLT between fPTC and sPTC samples was significant (p < 0.001) (Mann-Whitney
U-test). Triangles represent the RTL of each case; the upper and lower lines represent the interquartile
range of the distribution (25th–75th percentile); the middle line represents the median.
BRAFV600E mutation was detected in 9/13 (69.0%) fPTC and 14/18 (78%) sPTC (p = 0.68), which
was not statistically significant. All HER2+ fPTC were BRAFV600E-positive (BRAF+), although not all
BRAF+ fPTC were HER2+ (Figure 4).
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Table 1. Characteristics of patients.
Tumor
Age at
Diagnosis
(Mean ± SD)
Sex
(Males %)
PTC Size
(Median/IQR) TNM
Extrathyroidal
Invasion N (%)
Multifocality
N (%)
Lymphonode
Metastases at
Diagnosis N (%)
Final Outcome * N (%) Follow-up(Mean Years) Histology
fPTC
(n = 13) 51.5 ± 17.0 6 (46.1%) 11/11.5
pT1 8 (61.5%)
pT2 2 (11.7%)
pT3 3 (23.0%)
5 (38.5%) 7 (53.8%) 3 (23%) Remission 9 (69.2%)Persistent disease 4 (30.8%) 7.59 ± 3.9
9 CV-PTC
4 FV-PTC
sPTC
(n = 18) 46.1 ± 8.5 3 (16.6%) 9.5/8.5
pT1 8 (44.4%)
pT2 1 (5.5%)
pT3 9 (50.%)
9 (50%) 6 (33.3%) 5 (27.7%) Remission 11 (61.1%)Persistent disease 2 (11.1%) 5.5 ± 2.8
14 CV-PTC
2 FV-PTC
1 SV-PTC
1 TR-PTC
CV-PTC—classical variant of papillary thyroid carcinoma; fPTC—familial papillary thyroid carcinoma; FV-PTC—follicular variant of papillary thyroid carcinoma; IQR—Inter
Quartile Range; N—number of cases; PTC—papillary thyroid carcinoma; sPTC—sporadic papillary thyroid carcinoma; SV-PTC—sclerosing variant of papillary thyroid carcinoma;
TNM—(Tumor (limph) Node Metastasis) classification [20]; TR-PTC: trabecular variant of papillary thyroid carcinoma; *—six patients were lost to follow-up.
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3. Discussion
Amplification of the HER2 gene in thyroid cancer was first uncovered by FISH analysis of
follicular cells from highly malignant PTC nodules [13]. They observed that HER2+ PTC exhibited
shorter telomeres than HER2− PTC. PTC is an entity mostly recognized as sporadic, although the
familial form may account for approximately 5% of cases [1,2]. Familial PTC may occur in combination
with other Mendelian cancer syndromes (familial adenomatous polyposis, Gardner’s syndrome,
Peutz-Jeghers syndrome, and Cowden’s syndrome) or may be unassociated with other neoplasms
in familial aggregates. However, although the risk of developing extra-thyroidal malignancy in
non-Cowden’s syndrome is documented [21,22], the clinical correlation between sporadic breast cancer
(20% of which are HER2+) [23] and PTC is still controversial [24,25], and the co-occurrence of both
disorders in the same individual is a subject of extensive debate [26,27]. None of our fPTC patients had
clinical or pathological evidence of hereditary syndromes associated with NMTC, breast cancer, or other
types of sporadic tumors, except for one male patient who had a previous squamous cell carcinoma of
the auricle. The thyroid cancer of this patient was not associated with any genetic alterations of the
genes examined here. As more than 5%, but fewer than 50%, of nuclei were found to be amplified in
our FFPE sections, we use the Vance criteria [17] in the interpretation of our results. Our data indicated
a significant difference in HER2 amplification (p = 0.019) in fPTC compared to sPTC. This finding
indicates a degree of genetic heterogeneity in the fPTC group and suggests that HER2+ cells in fPTC
possibly undergo apoptosis to a lesser extent than in sPTC. The observation adds thyroid carcinoma
to the list of tumors that exhibit HER2+. HER2+ is indeed observed in a growing number of other
tumors, including advanced gastric and esophageal cancer [28], ovarian [29], colon [30], bladder, lung,
uterine, cervix, head and neck, and endometrial cancer [31]. The extracellular domain of the HER2
receptor has an essential role in cell proliferation and anti-apoptotic processes, making HER2+ breast
and gastric/gastroesophageal cancers more likely to respond to targeted therapies in combination
with chemotherapy than HER2− tumors. A wide range of solid tumors showing deregulation of
HER2 expression are regarded as biologically aggressive. Familial PTC is often associated with a
more severe phenotype than its sporadic counterpart [32], and often harbor BRAFV600E mutation.
BRAFV600E is considered to have a prognostic value in PTC [33], and usually identifies differentiated
thyroid tumors with advanced clinicopathological features. BRAFV600E is also strongly associated with
PTC patient mortality [15]. In contrast to lung adenocarcinoma, in which HER2 amplification and
BRAFV600E mutation appear to be mutually exclusive events [34], here we found that all HER2+ fPTC
bore the BRAFV600E mutation, although not all BRAFV600E-positive nodules had HER2 amplification.
Of significance, none of the BRAFV600E-positive sPTC were HER2+, despite the high frequency of
BRAFV600 mutations in this cohort. It is not entirely clear how this discrepancy should be interpreted,
considering the limited size of our cohorts. In addition, we do not know whether HER2 amplification
and BRAFV600E mutation coexist in the same cells within a tumor or if they are segregated in different
clones. We do not know, either, if the condition is different in our HER2+ fPTC versus sPTC with
HER2+ cells <5%.
The other evaluated genes, ALK, BRAF, ETV6, and RET, exhibited extensive integrity. The only
case bearing a RET disruption was BRAFV600E-negative. Moreover, we found a significant difference
(p < 0.001) of RTL in fPTC nodules compared to sPTC nodules, in agreement with our previous
investigations [14,35]. Telomere length regulation plays a crucial role in genome instability and
tumorigenesis [36]. Dysfunctional telomeres can increase chromosome instability by causing either
fusion of chromosomes or fusion of sister chromatids, bringing the formation of anaphase bridges and
the beginning of the so-called breakage-bridge-fusion cycles [37]. Although biased by the small number
of patients investigated in our two cohorts (forced by the low frequency of fPTC), our data stigmatize
significantly shorter RTL in fPTC cells versus sPTC cells. This result is in line with the reported
predisposition of fPTC patients toward spontaneous chromosome fragility [35]. This observation poses
the basis for further investigation exploring the existence of a possible specific three-dimensional
(3D) altered telomere organization in fPTC. Telomere remodeling is a feature of cancer cells [38] and
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may identify tumor subgroups [39,40]. On the other hand, alterations in the telomere 3D profile
have been reported in a murine model of thyroid tumors [41]. Recurrent somatic mutations in the
promoter of TERT, the catalytic subunit of the enzyme telomerase, has been reported in PTC [42],
often in concomitance with mutated BRAF [43]. A subclonal distribution in the rare PTC that harbor
the alteration, in contrast to a clonal distribution in the poorly-differentiated and anaplastic tumors
has been observed [44]. Unfortunately, the scanty material available from our cases prevented the
possibility to establish a putative association of TERT promoter mutations with telomere length in
our PTCs.
Our finding on RTL are, substantially, in keeping with the Sugishita data [13]. However, in contrast,
38.5% of our fPTC, but none of our sPTC, showed HER2 amplification, indicating an apparently
preferential association with fPTC. In this regard, the small number of patients investigated in our
two cohorts might constitute a bias. Nevertheless, as a whole, the finding of BRAFV600E mutation in
association with HER2+ genetic heterogeneity, short telomere length, and prevalence of multifocal
tumors seems to not be a rare molecular event in fPTC and may characterize a subgroup of fPTC.
The response of refractory fPTC patients of this subgroup to target therapy of trastuzumab and
lapatinib should be explored.
4. Materials and Methods
4.1. Sample Collection
The PTCs (13 fPTC and 18 sPTC) considered in the present study were selected from the
pathological files of the University of Siena. Familial recurrence of the disease was defined as the
presence of at least one first-degree relative with differentiated thyroid carcinoma in the absence of
any other familial syndrome. None of the fPTC patients presented with any other sporadic tumor,
including breast cancer, except for one male patient with a previous squamous cell carcinoma of the
auricle. The histology of all tumor samples was classified according to the World Health Organization
guidelines [20]. The fPTC cases were selected from 13 families, randomly choosing one affected subject
from each family (the oldest affected subject): seven females (mean age at diagnosis of 53.7 ± 14.2,
with an age range of 29–69 years) and six males (mean age at diagnosis of 49.0 ± 21.5, range 24–81).
Four fPTC tumors were classified as follicular variants and nine were classical PTC. Seven out of the
13 families (53.8%) had three or more affected members, two out of 13 (15.3%) had two members
with PTC and at least three members operated for multi-nodular goiter, and four out of 13 had only
two members affected by thyroid cancer. In these cases, the phenomenon of genetic anticipation was
observed with the second generation acquiring the disease at an earlier age and having more advanced
disease at presentation.
The sPTC cases were from 15 females (mean age at diagnosis of 46.6 ± 7.8, range 31–64) and three
males (mean age at diagnosis 43.6 ± 13.6, range 31–58). Fourteen were classified as classical PTC,
two as follicular variants, one as a diffuse sclerosing variant, and one as a trabecular variant (Table 1).
Informed consent was obtained from each patient after a full explanation of the purpose and nature
of all of the procedures to be used. All data from the patients were handled in accordance with local
ethical committee-approved protocols and in compliance with the Helsinki declaration
4.2. Fluorescence In Situ Hybridization
Thick sections (30 µm) were obtained from formalin-fixed paraffin-embedded (FFPE) tissue
blocks of the thyroid nodules or, to assess probe cut-off, from the apparently tumor-free tissue of the
contralateral lobe. Nuclei were isolated as reported [45], and were investigated by FISH, using specific
probes and a standard protocol [46].
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4.3. Detection of HER2 Gene Copy Number Alterations or Amplification
HER2 amplification was determined by counting the total numbers of HER2 and CEP17
(chromosome 17 centromere-specific alphoid repetitive DNA, Abbott Molecular, Abbott Park, IL,
USA) signals per nucleus with a mean of 89.5 (range 34–175) nuclei. The ratio of HER2 signals to CEP17
(centromeric probe for chromosome 17) signals was calculated according to ASCO/CAP (American
Society of Clinical Oncology/College of American Pathologists Guideline) criteria refined for breast
cancer [16].
Nodules with, or suspected to have, HER2 amplification were then re-evaluated by FISH on 4
µm histological sections to assess the distribution of possible clones. The tumor area, marked by the
pathologist [47], was entirely scored. As more than 5%, but fewer than 50%, of nuclei were found to be
amplified, the Vance criteria were used to define the distribution of abnormal cells [17].
Consecutive histologic sections were used to assess HER2 expression by immunohistochemistry.
The expression of HER2 protein was determined using anti-c-erbB2 antibody (Dako, Glostrup,
Denmark) in accordance with the manufacturer’s instructions.
Detection of ALK, BRAF, ETV6, and RET rearrangements. Commercially available break-apart
or single gene probes for ALK, BRAF (Abbott Molecular, Abbott Park, IL, USA), and ETV6 (Kreatech
Diagnostic, Amsterdam, The Netherlands) were used to verify gene integrity in nuclei isolated from
FFPE tissue blocks. An arbitrary cut-off of 3% was employed, as control cells showed no split signal in
200 scored nuclei per sample. For the RET gene, a homebrew probe and a previously described cut-off
value were used [19]. Microscopic analysis was performed with an Olympus BX41 epifluorescence
microscope and a charge-coupled device camera (Cohu, San Diego, CA, USA) interfaced with the
CytoVision system (software version 3.9; Applied Imaging, Pittsburg, PA, USA).
4.4. Telomere Length and BRAFV600E Mutation
DNA was extracted from fresh or FFPE tissues, using the QIAamp® DNA Mini Kit (Qiagen,
Milano, Italy) following the manufacturer’s instructions. RTL of sPTC was determined by quantitative
PCR, carried out on 30 ng/µL genomic DNA using an MJ Mini Personal Thermal cycler (Bio-Rad,
Milano, Italy) as described [14]. RTL values of the fPTC examined in the present study were reported
previously [14]. Relative telomere length was calculated as the ratio of telomere repeats to a single-copy
gene in experimental samples using standard curves. This ratio is proportional to the average telomere
length. The 36B4 gene, which encodes acidic ribosomal phosphoprotein P0, was used as the single-copy
gene [14]. For analysis of the BRAFV600E mutation, DNA was amplified in a final volume of 50 µL of
2× PCR Master Mix (AmpliTaq Gold® PCR Master Mix, Applied Biosystems, Milano, Italy) and a final
primer concentration of 200 nM. Primer sequences, PCR conditions, and interpretation of results were
as previously described [48].
4.5. Statistical Analyses
Mann-Whitney U-test (IBM SPSS Statistic version 2.1 software, Armonk, NY, USA) was used for
statistical analysis of differences in RTL. Fisher exact test was used to compare HER2 gene amplification.
All p-values were two-sided and p less than 0.05 was considered significant.
Epidemiological data are presented as the mean ± SD and median when necessary. The t-test
for independent data was performed for normal variables. To evaluate significant differences in data
frequency we analyzed 2 × 2 contingency tables by the Fisher exact test. Tables with sizes larger than
2 × 2 were examined by the Chi-squared test.
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